ASAQ Launch

[ March 2007 ]
Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use, accessible as a non patented drug, and available at an affordable price.

Une nouvelle association à doses fixes, à une prise par jour, maintenant disponible contre le paludisme

[ Paris – 1er mars 2007 ]
Sanofi-aventis et la fondation Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui que ASAQ, la nouvelle association fixe d’artésunate (AS) et d’amodiaquine (AQ), sera bientôt disponible à travers l’Afrique sub-saharienne. ASAQ est le premier médicament développé par les partenaires “FACT” (“Fixed-dose, Artemisinin-based Combination Therapy”) coordonnés par DNDi en partenariat avec sanofi-aventis.
[English]

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

[ Paris – March 1st, 2007 ]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), will soon be available throughout sub-Saharan Africa. ASAQ is the first drug developed by the FACT (Fixed-dose, Artemisinin-based Combination Therapy) partners, managed by DNDi in partnership with sanofi-aventis.
[Français]

ICOPA XI


[
 6-11 August 2006 ]
Glasgow, Scotland

11th International Congress of Parasitology.